Editorial - Phase II Study of Sunitinib in Men with Advanced Prostate Cancer
BERKELEY, CA (UroToday.com) - In the Annals of Oncology, Dr. Dror Michaelson and associates reported Phase II data on the efficacy and safety of the tyrosine kinase inhibitor sunitinib in patients with castration-resistant prostate cancer (CRPC).
 | Written by Christopher P. Evans, MD, a Contributing Editor with UroToday. |
|
UroToday, 1802 Fifth Street, Berkeley CA 94710 510.540.0930 (fax), info@urotoday.com ISSN 1939-4810
Privacy Policy | © 2009 UroToday ® All Rights Reserved |
